^




    Show legend
    Group by Gene:
    Include preclinical:

    bevacizumab-maly
    bevacizumab
    bevacizumab-adcd
    		0
    VEGF-A inhibitor
    bevacizumab-awwb
    Aybintio (bevacizumab biosimilar)
    Krabeva (bevacizumab biosimilar)
    bevacizumab-bvzr
    nivolumab
    PD1 inhibitor
    		1
    PD1 inhibitor
    pembrolizumab
    dostarlimab
    toripalimab
    mTOR inhibitor
    		2
    mTOR inhibitor
    everolimus
    temsirolimus
    sirolimus
    cabozantinib tablet
    		3
    Multi-tyrosine kinase inhibitor
    pazopanib
    cabozantinib capsule
    4
    IFNα stimulant, VEGF-A inhibitor
    bevacizumab + pegylated interferon α -2a
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    5
    VEGFR inhibitor, PD1 inhibitor
    pembrolizumab + axitinib
    6
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    7
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    8
    c-MET inhibitor
    c-MET inhibitor
    savolitinib
    9
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    10
    HIF-2α inhibitor
    belzutifan
    11
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    12
    VEGFR inhibitor
    VEGFR inhibitor
    axitinib
    13
    EGFR inhibitor
    erlotinib
    14
    ALK inhibitor
    crizotinib
    alectinib
    PD-L1 inhibitor
    		15
    PD-L1 inhibitor
    atezolizumab
    avelumab
    16
    CD70-targeted CAR-T immunotherapy
    ALLO-316
    17
    PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab + cabozantinib tablet
    18
    PARP inhibitor
    olaparib
    19
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    20
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    21
    HDAC inhibitor, Multi-tyrosine kinase inhibitor
    pazopanib + CG-781
    22
    PD1 inhibitor, IDO1 inhibitor
    pembrolizumab + INCB024360
    nivolumab + BMS-986205
    23
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    24
    VEGF-A inhibitor, PI3Kγ inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    bevacizumab + albumin-bound paclitaxel + IPI-549
    25
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    26
    VEGFR inhibitor, mTOR inhibitor
    temsirolimus + axitinib
    27
    FGFR inhibitor
    ABSK091
    28
    BRAF inhibitor
    vemurafenib
    29
    HIF-2α antagonist
    PT2385
    30
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    31
    Immunotherapy
    Immunotherapy
    32
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    33
    VEGF inhibitor
    VEGF inhibitor
    34
    VEGFR inhibitor, Immunotherapy
    Immunotherapy + VEGFR inhibitor
    35
    Glutamate inhibitor
    Glutamate inhibitor
    36
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    37
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    38
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    39
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    40
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    everolimus + lenvatinib
    41
    CD122 agonist, IL-2 stimulant
    aldesleukin
    42
    VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
    tivozanib
    43
    TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-014
    44
    PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
    bevacizumab + atezolizumab + IPI-549
    45
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    46
    VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sunitinib + pazopanib
    47
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    48
    pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sorafenib + sunitinib
    49
    TGM2 inhibitor
    MD102
    50
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    51
    CYP17A1 inhibitor
    abiraterone acetate
    52
    PRC2 inhibitor
    MRTX2219
    53
    RAC1 inhibitor
    NSC23766
    54
    UCHL1 inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + 6RK73
    55
    pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + 4-methylumbelliferone
    56
    ATR inhibitor
    M6620
    57
    DNA synthesis inhibitor
    cisplatin
    No biomarker
    MET amplification
    MET mutation
    MET fusion
    MET expression
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 underexpression
    PBRM1 mutation
    PBRM1 deletion
    PBRM1 negative
    PBRM1 overexpression
    PBRM1 underexpression
    MTOR mutation
    KDR rs2071559
    MTOR overexpression
    KDR expression
    KDR C482R
    MTOR Q2223K
    KDR overexpression
    FLT1 rs9554320
    FLT1 expression
    FLT1 overexpression
    AXL-L
    ARID1A mutation
    ROBO3 mutation
    AXL overexpression
    AXL expression
    PD-1 expression
    ALK rearrangement
    VHL mutation
    TSC2 mutation
    HMOX1-L
    HMOX1 expression
    TSC1 deletion
    TSC1 mutation
    TSC2 H1620R + TSC2 Y1650C
    HGF-L
    HGF expression
    HGF-H
    PD-1-H
    VHL promoter methylation
    VHL deletion
    LRP1B mutation
    MSI-H/dMMR
    BRCA1 mutation
    BRCA2 mutation
    KIM1 expression
    FLCN mutation
    TFE3 translocation
    HDAC2 expression
    ERVE-4 expression
    HAVCR2 expression
    SPP1-L
    CXCL8-L
    IL6-L
    IL18 expression
    ANGPT2 expression
    TIMP1 expression
    CSF1 expression
    VEGFA expression
    CXCL9 expression
    IL18BP expression
    SYNE1 mutation
    CDKN2A mutation
    CEACAM1 overexpression
    CXCL10 overexpression
    CA9 expression
    CD31 expression
    GNAQ mutation
    IKZF2-L
    KDM5C mutation
    PDGFRA expression
    CD8 expression
    HIF1A expression
    ELTD1 expression
    BAP1 negative
    IL6R L
    IL6ST-H
    TFEB translocation
    EWSR1-POU5F1 fusion
    KMT2C mutation
    LDH elevation
    CTLA4 promoter hypomethylation
    NANOGNB mutation
    PARP1 underexpression + PBRM1 mutation
    PTTG1 overexpression
    TNFRSF9 elevation
    PD-L1 expression + CD14 positive
    LAG3 positive + CD4 positive
    TNFRSF9 positive + CD8 positive
    TNFRSF9 positive + CD4 positive
    NF2 mutation
    FH mutation
    FOLH1 overexpression
    KHDRBS1 overexpression
    PECAM1 underexpression
    CD3G overexpression
    NCAM1 overexpression
    CD4 underexpression
    PBRM1 mutation + SETD2 mutation
    TERT promoter mutation
    BRAF mutation
    miR-138 underexpression + miR-497 overexpression
    SETD2 mutation + TP53 mutation
    CXCL8 elevation
    VEGFA-H
    BAP1 mutation
    TERT overexpression
    KIM1 elevation
    IL6-H
    CXCL10-H
    CDKN2A deletion
    BAP1 deletion
    FLCN deletion
    VEGFA overexpression
    IL6 elevation
    SETD2 mutation
    VEGFA elevation
    Tregs-H
    DDR
    T-cell-inflamed GEP signature
    IFNG gene signature overexpression
    BONSAI high signature
    PAI1-H
    HLA-A*03
    HAS3 expression
    DAPK1 underexpression
    miR-155 underexpression
    SMARCA4 mutation
    KDM6A mutation
    CCNE1 amplification
    CTBP1 deletion
    ACRBP amplification
    PLK1 overexpression
    GNAS amplification
    MCAM overexpression
    LRP10 deletion
    SULT1A3 amplification
    TP53 expression
    CXCL11-H
    EPAS1 overexpression
    DDX39B overexpression
    FGFR1 overexpression
    AXL overexpression + PD-L1 expression
    TP53 mutation
    UGT1A9 expression
    CXCL13 elevation
    TNFSF13B elevation
    TMB-H
    CD44 positive
    CD44 expression
    ADCYAP1 deletion
    IL7 elevation
    CXCL12-H
    NT5E overexpression
    CD70 expression
    PTEN deletion
    IL13RA2 overexpression
    CXCR4 overexpression
    TGM2 overexpression
    PRCC-TFE3 fusion
    MTA2 overexpression
    PGF overexpression
    VEGFC underexpression
    PDGFA underexpression
    LAG3 expression
    FLT4 overexpression
    CCL4 elevation
    CD27 overexpression
    VEGFD overexpression
    AR-V7 positive
    VEGFB overexpression
    Chr del(9)(p21.3)